Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | KMO | O15229 | 3/20 | 0.43 |
| ▸ | KYNU | Q16719 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180582 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1G6PDCASP7 | |
| SCHEMBL29934345 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1G6PDCASP7 | |
| SCHEMBL16616577 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1G6PDCASP7 | |
| SCHEMBL17641540 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1G6PDCASP7 | |
| SCHEMBL30973707 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1G6PDCASP7 | |
| SCHEMBL134058 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1G6PDCASP7 | |
| SCHEMBL29352838 | 1.00 | KDM4E (1.00) | KDM4EHIF1ATDP1G6PDCASP7 | |
| Water SCHEMBL8081334 | 0.98 | KDM4E (0.97) | KDM4EHIF1ATDP1G6PDCASP7 | |
| Kynurenine SCHEMBL6932225 | 0.87 | KDM4E (0.77) | KDM4EHIF1ATDP1G6PDCASP7 | |
| SCHEMBL19260994 | 0.86 | KDM4E (0.75) | KDM4EHIF1ATDP1G6PDCASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572737-A1 | METHODS OF USING A SMALL MOLECULE CHEMICAL COMPOUND TO REDUCE THE APPEARANCE OF RHYTIDS AND WRINKLES | Birchbiomed Inc. (CA) | 2025-06-25 | — | — | EP | claimed |
| CN-120019060-A | Compounds and their use for filtering ultraviolet and/or high-energy visible light | 索利奥美公司 | 2025-05-16 | — | — | CN | claimed |
| CN-118566488-A | Reagent combination for detecting depression, manufacturing method, detection system and application thereof | 合肥歆智医疗器械有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-118294676-A | Depression detection reagent based on key marker, detection system and application thereof | 合肥歆智医疗器械有限公司 | 2024-07-05 | — | — | CN | claimed |
| WO-2024055116-A1 | METHODS OF USING A SMALL MOLECULE CHEMICAL COMPOUND TO REDUCE THE APPEARANCE OF RHYTIDS AND WRINKLES | BIRCHBIOMED INC. (CA) | 2024-03-21 | — | — | WO | claimed |
| WO-2024003412-A1 | METHODS FOR DETERMINING IMPAIRMENTS IN NEURO-METABOLISM IN A SUBJECT IN NEED THEREOF & MEANS USEFUL IN THE TREATMENT THEREOF | HEALTHY-LONGER GMBH (CH) | 2024-01-04 | — | — | WO | claimed |
| WO-2023114656-A1 | METHODS FOR TREATING AND PREVENTING DISEASES AND DISORDER THROUGH MODULATION OF NAD | MARK PAUL (US) | 2023-06-22 | — | — | WO | claimed |
| EP-4018200-A1 | METHODS, KITS AND COMPOSITIONS FOR DIAGNOSING AND TREATING RENAL DISEASE | Hill's Pet Nutrition, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| US-20220187315-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING DEPRESSION | DUKE UNIVERSITY | 2022-06-16 | — | — | US | claimed |
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-3349750-B1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12601931-B2 | Photo-biomodulation by endogenous auto-fluorescent compounds | PHOTOPROTECTIVE TECHNOLOGIES INCORPORATED (US) | 2026-04-14 | — | — | US | disclosed |
| US-12551459-B2 | Combination of kynurenine and antigen presenting cells (APC) as therapeutics and methods for their use in immune modulation | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-02-17 | — | — | US | disclosed |
| US-20220071559-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | GLAS USA LLC | 2022-03-10 | — | — | US | disclosed |
| US-20220071894-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | BT BIDCO LLC | 2022-03-10 | — | — | US | disclosed |
| US-11267824-B2 | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-03-08 | — | — | US | disclosed |
| CN-110731966-B | Application of clematis chinensis glycoside in medicine for treating liver injury caused by triptolide | 中国药科大学 | 2022-03-08 | — | — | CN | disclosed |
| CN-114127066-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022026450-A1 | ASSESSMENT AND TREATMENT OF DEPRESSION, ANXIETY, OR RELATED DISORDERS | DUKE UNIVERSITY (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551459-B2 | Combination of kynurenine and antigen presenting cells (APC) as therapeutics and methods for their use in immune modulation | AADAT, IDO1, IAPP | KDM4E 1466/4885HIF1A 1602/4885TDP1 3336/4885 |
| US-12601931-B2 | Photo-biomodulation by endogenous auto-fluorescent compounds | B2M, CRYZ, NEFM | KDM4E 3906/4885HIF1A 1798/4885TDP1 3968/4885 |
| US-20220071894-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | ACKR3, CXCR2, CXCR3 | KDM4E 4854/4885HIF1A 3894/4885TDP1 3702/4885 |
| US-20220071559-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | TPMT, FABP2, SLC10A2 | KDM4E 3871/4885HIF1A 4826/4885TDP1 2714/4885 |
| US-11267824-B2 | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | IDO2, IDO1, TDO2 | KDM4E 1390/4885HIF1A 1717/4885TDP1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.